Innate immune system activation in osteoarthritis: Is osteoarthritis a chronic wound?

Current Opinion in Rheumatology

Volumn 20, Issue 5, 2008, Pages 565-572

  Scanzello, Carla R ^a,b   Plaas, Anna ^b   Crow, Mary K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Inflammation; Innate immunity; Osteoarthritis; Synovium; Toll like receptor

Indexed keywords

AGGRECANASE; CYTOKINE; FIBRONECTIN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PROTEINASE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR;

ARTHROPATHY; ARTICULAR CARTILAGE; CARTILAGE; CARTILAGE CELL; CATABOLISM; CHRONIC WOUND; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; INNATE IMMUNITY; JOINT FUNCTION; KNEE OSTEOARTHRITIS; NONHUMAN; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STIMULUS; SYNOVITIS; TISSUE INJURY; WOUND HEALING; CHRONIC DISEASE; IMMUNE SYSTEM; IMMUNOLOGY; PATHOLOGY;

CHRONIC DISEASE; HUMANS; IMMUNE SYSTEM; OSTEOARTHRITIS; WOUND HEALING;

EID: 55249086740     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32830aba34     Document Type: Review

References (70)

1. Hill CL, Hunter DJ, Niu J, et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 2007; 66:1599-1603. This imaging study of close to 300 patients with knee osteoarthritis documents a relationship between changes in synovitis and pain scores in a longitudinal manner. This report follows up this group's original cross-sectional analysis published in 2001, which was one of the first to demonstrate an association of synovial changes (seen on imaging) with symptoms in osteoarthritis patients.
2. Ayral X, Pickering EH, Woodworth TG, et al. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005; 13:361-367.
3. van Lent PL, Blom AB, van der Kraan P, et al. Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation. Arthritis Rheum 2004; 50:103-111.
4. Roelofs MF, Abdollahi-Roodsaz S, Joosten LA, et al. The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions. Arthritis Rheum 2008; 58:338-348. Thisisa very recent in-depth synthesis of the available data on TLR signalingin driving RA, seronegative spondyloarthropathies, and systemic lupus erythamatosis. Although there may be substantial differences in the pattern of activation and downstream effects of TLR pathways in osteoarthritis compared with these rheumatic conditions, the information contained herein is relevant to the future study of these pathways in joint tissues from other disorders.
5. Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR. Early events in the recognition of danger signals after tissue injury. J Leukoc Biol 2008; 83:546-552. This review is a concise summary of the role of TLR-4 and molecular 'danger signals' (DAMPs) in models of injury, including hemorrhagic shock, femur fracture, and ischemia/reperfusion. It is a summary of recent data presented at the Seventh World Conference on Trauma, Shock, Inflammation, and Sepsis.
6. Pearle AD, Scanzello CR, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15:516-523.
7. Walsh DA, Bonnet CS, Turner EL, et al. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007; 15:743-751. This article describes the relationships between inflammation and angiogenesis in different locations within the joint affected by osteoarthritis.
8. Pessler F, Dai L, Diaz-Torne D, et al. The synovitis of 'noninflammatory' orthopedic arthropathies: a quantitative histologic and immunohistochemical analysis. Ann Rheum Dis. 2008 [Epub ahead of print]. doi:10.1136/ard.2008.087775. This is one of the first papers to systematically evaluate synovial inflammation seen in osteoarthritis, 'orthopedic' arthropathies (i.e. meniscal/ligamentous injuries, AVN, fracture) and normal adult synovium side by side. The strength of this report is the use of a validated histopathologic scoring system, and quantitation of specific cell types after immunocytochemical staining.
9. Rollin R, Marco F, Jover JA, et al. Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol Int 2008; 28:757-764.
10. Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8:R187. doi:10.1186/ar2099.
11. Sturmer T, Brenner H, Koenig W, Gunther KP. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis 2004; 63:200-205.
12. Sowers M, Jannausch M, Stein E, et al. C-Reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002; 10:595-601.
13. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000; 43:1916-1926.
14. Fell HB, Jubb RW. The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum 1977; 20:1359-1371.
15. Dingle JT, Saklatvala J, Hembry R, et al. A cartilage catabolic factor from synovium. Biochem J 1979; 184:177-180.
16. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007; 23:435-461. This is a comprehensive overview of hyaluronan in tissue homeostasis and injury, and puts hyaluronan in the context of the 'DAMPs'. This review, from a laboratory that has published an extensive body of work on animal models of lung injury, covers hyaluronan structure, regulation, synthesis, and turnover as well as its role in immunoregulation.
17. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201:1135-1143.
18. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-561.
19. Clynes R, Moser B, Yan SF, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7:743-751.
20. Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005; 52:2376-2385.
21. Brown MP, Trumble TN, Plaas AH, et al. Exercise and injury increase chondroitin sulfate chain length and decrease hyaluronan chain length in synovial fluid. Osteoarthritis Cartilage 2007; 15:1318-1325. This study demonstrates the changes that occur to hyaluronan species in the synovial fluid of race horses after osteochondral injury, or with exercise. Aggressive exercise training induces molecular changes in hyaluronan similar to that seen in disease states.
22. Belcher C, Yaqub R, Fawthrop F, et al. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann Rheum Dis 1997; 56:299-307.
23. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002; 21:15-23.
24. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 20:499-508.
25. Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem 2008; 283:6058-6066.
26. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004; 279:26991-27007.
27. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277:41046-41059.
28. Taylor KR, Trowbridge JM, Rudisill JA, et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279:17079-17084.
29. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007; 282:18265-18275. This is a very informative study from our colleagues in dermatology. The series of experiments described provide convincing evidence that hyaluronan mediates proinflammatory effects through TLR-4 independently of LPS. Furthermore, two murine models of sterile skin injury are described, and evidence suggestive of a role for hyaluronan/TLR-mediated signals in these models is presented.
30. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-1179.
31. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296:155-158.
32. Zhang X, Shan P, Qureshi S, et al. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 2005; 175:4834-4838.
33. Termeer CC, Hennies J, Voith U, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165:1863-1870.
34. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111.
35. Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006; 177:1272-1281.
36. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1-14.
37. Pagani F, Zagato L, Maier JA, et al. Expression and alternative splicing of fibronectin mRNA in human diploid endothelial cells during aging in vitro. Biochim Biophys Acta 1993; 1173:172-178.
38. Muro AF, Chauhan AK, Gajovic S, et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol 2003; 162:149-160.
39. Kriegsmann J, Berndt A, Hansen T, et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int 2004; 24:25-33.
40. Chevalier X, Groult N, Hornebeck W. Increased expression of the Ed-B-containing fibronectin (an embryonic isoform of fibronectin) in human osteoarthritic cartilage. Br J Rheumatol 1996; 35:407-415.
41. Pulai JI, Chen H, Im HJ, et al. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005; 174:5781-5788.
42. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-10233.
43. Lasarte JJ, Casares N, Gorraiz M, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007; 178:748-756.
44. Gondokaryono SP, Ushio H, Niyonsaba F, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 2007; 82:657-665. Although fibronectin/TLR binding has been demonstrated in vitro in the past, this recent work is the first to implicate this specific interaction in the development of arthritis, using a mouse model.
45. Matsumura T, Degawa T, Takii T, et al. TRAF6-NF-kappaB pathway is essential for interleukin-1-induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes. Immunology 2003; 109:127-136.
46. Ojaniemi M, Liljeroos M, Harju K, et al. TLR-2 is upregulated and mobilized to the hepatocyte plasma membrane in the space of Disse and to the Kupffer cells TLR-4 dependently during acute endotoxemia in mice. Immunol Lett 2006; 102:158-168.
47. Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004; 50:3856-3865.
48. Ozawa T, Koyama K, Ando T, et al. Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/ dexamethasone. Mod Rheumatol 2007; 17:459-463. This is a very small in-vitro study, but is one of the very few addressing TLR activity on synovial fibroblasts from osteoarthritis in addition to RA patients.
49. Kyburz D, Rethage J, Seibl R, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003; 48:642-650.
50. Kim HA, Cho ML, Choi HY, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006; 54: 2152-2163.
51. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008; 118:205-216. This interesting study demonstrates the complexity of TLR-2 and TLR-4 immunoregulation in a model of autoimmune arthritis. Evidence is presented that these TLRs may differentially drive regulatory versus inflammatory T-cell responses, suggesting there may be complex interaction between these two pathways in vivo. Although this is not an osteoarthritis model, the evidence presented has implications for TLR-mediated processes in other contexts that will need future clarification.
52. Amos N, Lauder S, Evans A, et al. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006; 45:1201-1209.
53. Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibro-blasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol 2007; 34:523-533. This is a follow-up study to [52] that extends the authors' findings to aggrecanase activity, as well as cytokine-driven mediator production.
54. Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007; 56:575-585.
55. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993; 36:1214-1222.
56. Chen LX, Lin L, Wang HJ, Wei XL, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008; 16:174-184. This is the first demonstration of NF-kB inhibition as a therapeutic strategy in a surgically induced rat model of osteoarthritis. It is a treatment study, as opposed to prevention, as NF-kB was inhibited after induction of disease. This treatment approach limited cartilage damage and synovial changes as observed 2 weeks after disease induction.
57. Plaas A, Osborn B, Yoshihara Y, et al. Aggrecanolysis in human osteoarthritis: confocal localization and biochemical characterization of ADAMTS5-hyaluronan complexes in articular cartilages. Osteoarthritis Cartilage 2007; 15:719-734.
58. Sandy JD. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 2006; 14:95-100.
59. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341:738-746.
60. Zhang Q, Hui W, Litherland GJ, et al. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008 [Epub ahead of print] doi:10.1136/ard.2007.079574. This very recent report is the first to show differential TLR expression in advanced osteoarthritis compared with normal cartilage, suggesting regulation of TLR activity in disease. In addition, the authors also demonstrate the ability of TLR-2 ligands to induce MMP-13 expression in chondrocytes.
61. Sacre SM, Andreakos E, Kiriakidis S, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007; 170:518-525.
62. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007; 8:283-292.
63. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 1996; 14:155-162.
64. Fujikawa Y, Shingu M, Torisu T, Masumi S. Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995; 54:318-320.
65. Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32:1317-1323.
66. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39:237-246.
67. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007; 34:1323-1327. This is the pilot study using TNF-a inhibition in the treatment of erosive osteo-arthritis of the hands. Although this small study did not demonstrate efficacy using ACR20 response criteria, there was evidence of a substantial improvement in certain individuals. The choice of outcome measure and long-standing disease of the patients may have influenced the results, but positive trends in this small study support a role for TNF activity in certain patients.
68. Jung YO, Cho ML, Kang CM, et al. Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. Immunol Lett 2007; 109:21-27. This in-vitro study demonstrates the importance of TLR signaling in IL-15 production by synoviocytes.
69. Blaney Davidson EN, Vitters EL, van den Berg WB, van der Kraan PM. TGF beta-induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad7. Arthritis Res Ther 2006; 8:R65.
70. Roman-Blas JA, Stokes DG, Jimenez SA. Modulation of TGF-beta signaling by proinflammatory cytokines in articular chondrocytes. Osteoarthritis Cartilage 2007; 15:1367-1377. These authors demonstrate IL-1b and TNF-a can influence TGF-b signaling pathways in chondrocytes in vitro. This study points to the complexity of interactions between catabolic and anabolic influences that likely exists in vivo.